Clinical use of -lactams has selected for -lactamase-producing organisms. Numerous -lactamases are known, and sequencing allows them to be divided into four Classes, A to D, with Classes A and C being the most important. Pharmaceutical chemists have responded to the spread of -lactamase-producing organisms by developing stable agents and inhibitors. Stability in penicillins and cephalosporins is achieved by attaching a bulky substituent to the amino group of 6-aminopenicillanic acid or 7-aminocephalosporanic acid, or by replacing the hydrogen on carbon 6 (penicillins) or 7 (cephalosporins) with an -methoxy group. In carbapenems, stability is achieved by incorporation of a simple trans-6-hydroxyethyl group.
Introduction
-Lactams account for approximately 50% of global antibiotic consumption and this heavy usage exerts considerable selection for resistance arising via (i) modification of the normal penicillin-binding proteins (PBPs), (ii) bypassing of the normal PBPs, (iii) impermeability of the Gram-negative organism outer membrane and (iv) production of -lactamases. Some bacteria, notably Pseudomonas aeruginosa, may owe their resistance to an ability to pump out -lactams 1,2 but details of this mechanism are only gradually being elucidated. PBP modification and bypassing are the most important mechanisms of resistance in Gram-positive cocci, but -lactamases are preeminent in Gram-negative species.
Diversity of -lactamases
Many -lactamases are known; a recent review 3 detailed over 190 types. Most function by a serine ester hydrolysis mechanism, as illustrated in Figure 1 , but a few use a zinc ion to attack the -lactam ring. Each species has its own chromosomal -lactamase, often made at insignificant levels; in addition many isolates have secondary -lactamases encoded by plasmids or transposons. Chromosomal and plasmid-borne -lactamases are usually distinct but some overlap occurs: in particular, SHV-1, the chromosomal enzyme of Klebsiella pneumoniae, is encoded by a plasmid in other Enterobacteriaceae, and AmpC enzymes, although chromosomal in many Enterobacteriaceae, are also increasingly being recorded from plasmids (see below).
Role of -lactamases in resistance
The ability of a -lactamase to cause resistance is enhanced by (i) rapid turnover of substrate (high k cat ), (ii) high affinity for the substrate (low K m ), (iii) large enzyme quantity, whether produced constitutively or via induction and (iv), in the case of Gram-negative bacteria, by low outer membrane permeability. The interplay of these factors can be represented mathematically for Enterobacteriaceae, 7, 8 but not for P. aeruginosa, 9 perhaps because the latter organism pumps out -lactams. 1 These topics are explored fully elsewhere. 10 The ability of an enzyme to cause resistance in vitro may also vary with the conditions. MICs of substrates tend to rise as the inoculum is increased: more cells make more enzyme and are better able to protect themselves. Such inoculum effects notoriously occur with penicillins for staphylococci, 11 but also for ureidopenicillins with Klebsiella spp., 12 for firstgeneration cephalosporins against Gram-negative bacilli having TEM enzymes 13 and for third-generation cephalosporins against isolates with extended-spectrum TEM and SHV enzymes. 14 In general, a major inoculum effect for a Table IV, and Frère   24 ). Inhibitors may simply yield acyl enzymes that fail to hydrolyse or may fragment after attachment to the active serine. 64, 65 Class B -lactamases function differently, using a zinc ion to attack the -lactam ring.
compound contraindicates its use in serious infections caused by the pathogen, though not necessarily for prophylaxis. Occasionally, the ability of a -lactamase to give protection varies with the pH 15 or with whether the medium is conducive to -lactamase induction.
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-Lactam use and the spread of -lactamases
Chromosomal -lactamases exist in bacteria collected before human antibiotic use and may have a minor role in cell-wall metabolism, or may protect against -lactams produced by environmental fungi. Whatever this natural function the major recent factor selecting for strains with these enzymes has been human use of -lactams, which has favoured bacteria that (i) produce large quantities of chromosomal -lactamases, (ii) have secondary, plasmidmediated, enzymes and/or (iii) have mutant -lactamases with an extended spectrum. Selection has sometimes favoured whole species, sometimes variants within a species. As resistance has spread, pharmaceutical chemists have responded by developing compounds with increased stability, or by protecting labile agents by inhibiting the -lactamases. In turn, these new agents have selected for new forms of -lactamase-mediated resistance. These cyclical processes of drug development and the emergence of resistance are discussed in the remainder of this review. Staphylococci were the first organisms in which -lactamases became a problem but subsequent cycles of selection have mostly concerned Gram-negative pathogens.
First-generation -lactams and early problems with -lactamases
When it was introduced in 1944, benzylpenicillin was active against about 95% of Staphylococcus aureusisolates but the remainder had -lactamase and were resistant. Within 5 years, the proportion of enzyme producers had grown to 50%, reflecting gene transfer and strain selection; 17 subsequently this proportion has risen to around 90%.
A similar spread of resistance followed introduction of -lactams active against Gram-negative organisms in the early 1960s. 18 Some pathogens are inherently resistant to these agents as a result of producing large quantities of chromosomal -lactamases. For example, ampicillin, amoxycillin and the carboxypenicillins (carbenicillin and ticarcillin) lack activity against Klebsiella spp., which have significant levels of SHV-1 or K1 chromosomal -lactamases (Tables II and III) . Likewise, ampicillin, amoxycillin and first-generation cephalosporins lack activity against species with inducible Class A enzymes, e.g. P. vulgaris and C. diversus, and against those with inducible AmpC enzymes, notably Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp., Serratia spp. and P. aeruginosa (Tables II and III) . These species gained clinical importance after -lactams with activity against other Gram-negative organisms entered use.
A more important sequel to the introduction of these -lactams was the spread of plasmid-mediatedlactamases, principally TEM-1, in species that initially were susceptible. TEM-1 enzyme was first recorded in Escherichia coli in 1965 18 and has since spread to 20-60% of isolates of Enterobacteriaceae; its exact frequency varies with species and locale (see Sanders & Sanders 19 and Livermore 10 for tables summarizing the current incidence of this enzyme). A few other plasmid-encoded -lactamases, notably TEM-2, SHV-1 and OXA-1, have also become widely scattered in Enterobacteriaceae but the TEM-1 enzyme is more than ten times as prevalent as any of these types. 10, 19 Numerous other types have been reported in a few isolates. By 1974-5, plasmids bearing the gene encoding TEM-1 -lactamase had spread to fastidious Gram-negative rods, pseudomonads and Vibrio cholerae. 18 TEM-1 remains the sole plasmid-mediatedlactamase present in gonococci, having been found in 1% to 40% of isolates, depending on the country. It occurs in 2-40% of isolates of Haemophilus influenzae, with the prevalence varying between countries and with the capsular type, and is at least ten times commoner than the one other -lactamase type (ROB-1) found in this bacterial species. 10, 19 Only among pseudomonads and Moraxella catarrhalis does TEM-1 lose its pre-eminence: PSE-1 and -4 are the commonest secondary -lactamases in P. aeruginosa and TEM -lactamases, although first recorded in 1969, still occur in 1% of isolates. 20 PSE-1 and -4 are often regarded as plasmid-encoded, but in fact are mostly determined by chromosomal inserts, and their dissemination-such as it is-reflects clonal spread, not gene transfer. 21 BRO-1 and -2 are the sole -lactamases to occur in M. catarrhalis. They were first found as recently as the late 1970s, but have since spread to 80% of isolates, with BRO-1 being ten times more common than BRO-2.
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Almost all the plasmid-encoded -lactamases mentioned above-TEM, TEM-2, SHV-1, PSE-1, PSE-4 and the BRO types-belong to Class A, the exception being OXA-1, which belongs to Class D (Table II) . All of them, including OXA-1, confer similar resistances, with activity against ampicillin, amoxycillin, ticarcillin and carbenicillin (Table III) . Unless the level of enzyme is exceptionally low, resistance to ureido-and piperazine-penicillins (azlocillin, mezlocillin and piperacillin) and first-generation cephalosporins is also expressed. Even where enzyme producers appear susceptible to these latter agents in vitro, their in-vivo efficacy is doubtful. 13, 23 ' -Lactamase-stable' penicillins and cephalosporins, and -lactamases that attack them Stability to -lactamases can be achieved by attaching to the -lactam ring a substituent that hinders access of the active-site serine or that displaces water from the active site, preventing completion of hydrolysis (Figure 1) . 24 Strategies to achieve these objectives include attaching a bulky acyl group to the amino group of 6-aminopenicillanic acid or 7-aminocephalosporanic acid, or replacing the hydrogen on carbon 6 (penicillins) or 7 (cephalosporins) with an -methoxy group. 25 Examples of these substitutions are shown in Figure 2 and their effects on -lactamase stability are detailed in Table IV . Staphylococcal penicillinase was overcome in the early 1960s with the development of methicillin and the oxacillins ( Figure 2 , Table IV ). Significant resistance to these agents has since emerged as a result of PBP bypass mechanisms, but not from -lactamases. The lack of extended-spectrum staphylococcal penicillinases may reflect biochemical impossibility or the enzyme's location: staphylococcal penicillinase is extracellular and acts to reduce the environmental drug concentration, with bacterial growth only recommencing once the drug concentration falls. 26 If a cell were to produce a mutant -lactamase with oxacillinase activity, for example, it would protect other organisms as well as itself and so would gain little individual advantage.
-Lactamase stability was harder to achieve in -lactams with activity against Gram-negative species than in those directed against staphylococci, largely because Gram-negative organisms produce a wider variety of -lactamases than do staphylococci (Table II) . Incorporating broad-spectrum stability proved particularly difficult with penicillins, the only one with such stability being temocillin, the 6--methoxy analogue of ticarcillin ( Figure 2 and Table IV ). The development of -lactamasestable cephalosporins has been more sucessful. An oxyimino-aminothiazolyl 7-acyl side chain (see cefotaxime in Figure 2 ) makes cephalosporins stable to TEM-1 and SHV-1 enzymes, and such groups are incorporated in most third-generation cephalosporins. Alternatively, a 7--methoxy group, as in cefoxitin (see Figure 2) , cefotetan, cefmetazole and latamoxef confers stability to TEM-1 and SHV-1 enzymes and to the CepA chromosomal -lactamase of Bacteroides fragilis (Table IV) . Oxyimino-aminothiazolyl and 7--methoxy groups were thought initially to confer stability to AmpC enzymes too, but it later became apparent that compounds with these substituents were efficiently hydrolysed under periplasmic conditions. 27 -Lactamase stability not only was difficult to achieve in compounds with activity against Gram-negative organisms, but also has proved impossible to maintain. This reflects the fact that the -lactamases of Gram-negative species are periplasmic and protect the individual cell. If a mutant makes more enzyme, or a 'better' enzyme, it gains individual advantage and may be selected. The first cephalosporin-resistant organisms to cause concern were mutants of Enterobacter spp., C. freundii, Serratia spp., M. morganii and P. aeruginosa that hyperproduced AmpC -lactamases. 19, 28, 29 Many newer cephalosporins are not stable to these enzymes (see above) and owe their activity against -lactamase-inducible (i.e. typical) strains to the fact that they do not induce enzyme synthesis. These compounds consequently select spontaneous 'derepressed' mutants, which hyperproduce enzyme without induction. The risk of selecting derepressed mutants during therapy is approximately 20% when third-generation cephalosporins are used to treat bacteraemia caused by Enterobacter spp. 30 and is probably higher in pneumonia, although negligible in urinary tract infections. 19 Derepressed mutants have become more prevalent: 5% of isolates of Enterobacter, Citrobacter and Serratia spp. were derepressed when extended-spectrum cephalosporins entered use, but subsequently, through a combination of repeated selection and strain spread, this proportion has since risen to 25-40% in major hospitals in North America and Western Europe 10, 19, 31 and to 70% in Athens. 32 The threat posed by AmpC -lactamases was assumed to be restricted to species where these enzymes normally are chromosomal and inducible. Recently, however, there have been several reports of plasmid-mediated AmpC enzymes in isolates of E. coli and in Klebsiella spp. Examples include BIL-1, CMY-1, -2 and -3, FOX-1, LAT-1, MIR-1 and MOX-1 enzymes. 3 DNA sequences vary among these plasmid-encoded AmpC enzymes, just as among chromosomal AmpC types, indicating that gene escape has occurred from separate species (Bauernfeind, A., personal communication). Enterobacteriaceae with plasmid-encoded AmpC enzymes are now widely scattered in the USA 34 and were found in eight of 966 Klebsiella spp. collected in a recent European survey of ICU isolates. 35 Enterobacteriaceae with high levels of AmpC enzyme, whether chromosomal or plasmid-encoded, typically are resistant to most cephalosporins, including 7-aminothiazolyl and 7--methoxy compounds, and to -aminopenicillins and monobactams (Table III) . Temocillin retains activity, as do carbapenems. Moderate activity is also retained by cefepime and cefpirome, but this is impaired if heavy inocula are tested.
36 Chromosomal -lactamase hyperproduction is also encountered in some isolates of Klebsiella oxytoca but in this case the enzyme, called K1 or KOXY, is a Class A type, not a Class C -lactamase. Hyperproducers have a characteristic antibiogram, being resistant to aztreonam and cefuroxime, moderately resistant to ceftriaxone, but remaining susceptible to ceftazidime as well as to cephamycins and carbapenems (Table III) . 10 During the mid-1980s, a second threat to ' -lactamasestable' oxyimino aminothiazolyl cephalosporins became apparent, with the emergence of extended-spectrum -lactamases (ESBLs), most of which are mutants of the classic TEM-1, TEM-2 and SHV-1 types.
37-39 These ESBLs have one to four amino acid replacements compared with their parent enzymes, and these changes sufficiently remodel the active site to allow attack on aminothiazolyl compounds (compare TEM-1 and TEM-3 Side-chain substitutions to confer -lactamase stability. (a) Substitution of the acyl group attached to the amino of 6-aminopenicillanic acid (left) or 7-aminocephalosporanic acid (right). Benzylpenicillin and cephalothin are labile to many -lactamases but methicillin and cefotaxime-with bulkier substituents-are more stable (Table IV) . (b) Addition of an -methoxy group at position 6 (penicillins) or 7 (cephalosporins). Temocillin and cephalothin, which lack this substituent, are labile to many -lactamases but their -methoxy analogues temocillin and cefoxitin are more stable (Table IV) .
vs cephalothin and cefotaxime in Table IV ). Over 45 TEM-and SHV-derived ESBLs are reported, numbered TEM-3 to -29, TEM-41 to -49 and SHV-2 to -7. The first major outbreak of such strains occurred in south-eastern France in 1985-7, 40 and was rapidly followed by further outbreaks in France and elsewhere. 37 ESBLs have since become most prevalent among klebsiellae, partly because these organisms resist desiccation on skin and fomites, facilitating cross-infection. 41 Thus a serotype K25 K. pneumoniae strain with SHV-4 -lactamase was transferred to at least 14 French hospitals, 42 and Burwen et al. 31 noted that producers commonly spread between tertiary hospitals and the peripheral centres with which they exchanged patients. Cross-infection does not, however, explain why so many different ESBL types have been found in klebsiellae, nor why some hospitals have recorded dissemination of single ESBLs among klebsiellae of diverse serotypes. In some cases plasmid spread, rather than cross-infection, has been the critical component in dissemination; 43, 44 moreover, identical ESBLs have evolved independently in different places. 45 ESBLs now occur in about 23% of klebsiellae from ICUs in Western and Southern Europe. 35 No single ESBL type predominates significantly: major outbreaks caused by producers of TEM-10, -12 and -26 have been widely reported in the USA and UK, as have those caused by TEM-3 producers in France; 38 overall, however, the SHV-2, -4 and -5 types may be the most widely scattered ESBLs in both Europe and the USA. 34, 46, 47 All the extended-spectrum TEM and SHV mutants attack aminothiazolyl cephalosporins and aztreonam as well as penicillins and first-generation cephalosporins.
-Methoxypenicillins and cephalosporins are spared (Tables III and IV) , as are carbapenems. Some variants (e.g. TEM-3, -4 and SHV-4 and -5) have equally strong activity against all aminothiazolyl agents whereas others (e.g. TEM-10 and -26) have a 'ceftazidimase' phenotype, being much more active against that compound than against cefotaxime and ceftriaxone; yet further types (e.g. TEM-12) have only marginal activity against any aminothiazolyl drug (Table III, 
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In vivo, resistance arises even though resistance in vitro is low-level (MICs 1-4 mg/L, compared with 0.01-0.12 mg/L for ESBL-negative, susceptible isolates). 14, 48 In view of these findings, it is prudent to avoid all non--methoxycephalosporins if ESBL production is suspected, irrespective of in-vitro susceptibility data.
The swift rise of strains with derepression of the AmpC -lactamase and of klebsiellae with extended-spectrum TEM and SHV enzymes reflects the fact that their resistance emerged repeatedly and spread from multiple foci: any organism with an inducible AmpC -lactamase can segregate derepressed mutants, and any TEM or SHV producer can segregate ESBL variants. Other -lactamases active against new-generation -lactams have been slower to spread. Nevertheless, a few such enzymes are beginning to cause concern. An important example is PER-1, a Class A type -lactamase remote from the TEM and SHV families. It was first described in a single P. aeruginosa isolate from a Turkish patient transferred to Paris, 49 but the gene has since been reported on at least four different plasmids from P. aeruginosa and salmonellae in Istanbul and Ankara. 50, 51 These reports have emerged without systematic search, suggesting that the enzyme is widespread in Turkey. If so, it is unlikely to remain confined there. Already, a similar enzyme, PER-2, has been described from salmonellae in Argentina. 5 2 P E R -1 and -2 both give resistance to aminothiazolyl cephalosporins, especially ceftazidime, and, unlike the TEM and SHV derivatives, are also active against ceftibuten. Penicillins are weak substrates, with piperacillin retaining activity in vitro (Table III) . Cephamycins are stable to these enzymes, as are carbapenems. Numerous other exotic ESBLs have been found on single occasions; examples include the FEC, FPM and FUR types from Japan, which resemble the chromosomal cefuroximases of K. oxytoca (K1 enzyme) and extended-spectrum Class D enzymes derived from OXA-2 and -10.
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Carbapenems and -lactamases active against them
Imipenem and meropenem have wider -lactamase stability than other -lactams, being effectively resistant to all the common plasmid-encoded Class A, C and D enzymes, including extended-spectrum TEM and SHV derivatives, PER-1 and AmpC types. This stability partly depends on the presence of a simple trans-6-hydroxyethyl group; analogues with acyl substituents or with the 6-hydroxyethyl in the cis configuration are less stable to -lactamases. 56 This -lactamase stability, coupled with rapid penetration to the target site and strong PBP affinity, gives carbapenems the broadest spectrum of any -lactams (Table III) . Moreover, unlike new cephalosporins, they are not prone to attack by mutants of -lactamase types that are already widespread, so -lactamase-mediated resistance has been slow to emerge and spread. Nevertheless, carbapenems are attacked by a few -lactamases, most notably the zinc (molecular class B) enzymes. Such enzymes are ubiquitous in several species (Table II) , of which only Stenotrophomonas maltophilia is common in clinical practice. Selection by carbapenems may have increased the prevalence of this species in some centres, but the organism remains a low-grade pathogen. A Class B -lactamase (CcrA or CfiA) is encoded by the chromosomes of 2-3% of B. fragilis isolates, although fewer than half of these organisms produce significant amounts of the enzymes. Copious expression of CcrA requires incorporation of an insertion sequence upstream of the -lactamase gene and this rearrangement occurs at high frequency in those organisms that have the -lactamase gene but do not produce the protein. 57 Since most bacteroides infection is endogenous, the potential for spread of 'outbreak' strains producing CcrA enzyme seems limited.
A more serious concern is the emergence of plasmidmediated Class B enzymes in Enterobacteriaceae and pseudomonads from Japan. The first such enzyme (unnamed) was from a P. aeruginosa isolate collected in 1988, 58 but a similar type, now called IMP-1, has since been found in Serratia marcescens and K. pneumoniae isolates as well as in P. aeruginosa. 59 This enzyme confers resistance to all -lactams except monobactams (Table  III) . It seems likely that this will spread in future, bringing to an end the era when carbapenems can overcome accumulated resistance to all other -lactams.
Carbapenemase activity also occurs in three closely related Class A -lactamases, Sme-1, 60 Imi-1 61 and NMC-A 62 (Table II) , isolated from rare Enterobacter cloacae and S. marcescens strains. Each of these enzymes is coded by chromosomally inserted DNA, and none gives substantial cross-resistance to cephalosporins (Table III) . For these reasons they seem a lesser threat than the IMP-1 zinc carbapenemase.
-Lactamase inhibitors
Protection of a labile -lactam with an inhibitor provides an alternative strategy for overcoming -lactamases. The idea is not new: combinations of ampicillin and oxacillin were occasionally used against P. aeruginosa urinary tract infections as early as 1963, based on the reasoning that oxacillin should inhibit the organism's AmpC enzyme, which otherwise destroys the ampicillin. 63 This combination was not very effective, probably because oxacillin penetrates P. aeruginosa poorly or is pumped out, and the strategy was dropped with the development of carbenicillin. Interest reawakened in the mid-1970s, when several classes of inhibitor were found in rapid succession, including clavams, penicillanic acid sulphones, halogenated penicillanic acids, olivanic acids and various penems (Figure 3 ) 64 . All of these -lactams bind to the active site of -lactamases, but are not efficiently hydrolysed. Some simply form acyl enzymes that fail to hydrolyse (see Figure  1 ). More often, however, 'suicide' kinetics are observed, with the acyl enzyme-inhibitor complex able either to undergo slow hydrolysis or to rearrange to yield a permanently inactivated species. 65 Enzyme molecules that achieve hydrolysis bind a further inhibitor molecule, again running the gauntlet of inactivation. Gradually, all of the enzyme is inactivated.
Of the inhibitor classes shown in Figure 3 , only clavams and penicillanic acid sulphones have been developed. Clavulanic acid is combined with amoxycillin and ticarcillin; sulbactam with ampicillin and cefoperazone; and tazobactam, a sulbactam derivative, with piperacillin. The preference for combining inhibitors with penicillins reflects the fact, already mentioned, that it is difficult to incorporate broad-spectrum -lactamase stability into these compounds. The activity of inhibitor combinations depends on at least five microbiological factors: (i) the susceptibility of the enzyme to inactivation; (ii) the amount of -lactamase present; (iii) the partner -lactam; (iv) the producer strain; and (v) the physicochemical conditions. These aspects have been reviewed previously 66 and are only outlined briefly here.
Susceptibility of -lactamases to inhibition
Clavulanate, sulbactam and tazobactam inhibit most Class A -lactamases, particularly the chromosomal enzymes of Bacteroides spp., C. diversus, Klebsiella spp., P. vulgaris, staphylococcal penicillinase and the classic and extendedspectrum TEM and SHV -lactamases (Table V; see also Payne et al. 67 ), although it should be noted that tazobactam and clavulanate are both ten-fold stronger inhibitors of TEM types than sulbactam. Some Class D -lactamases are also inhibited by clavulanate and sulphones, but activity against Class C types is poor among the sulphones and absent from clavulanate. An exception is the AmpC enzyme of M. morganii, which is rather susceptible to tazobactam 68 with the result that AmpC-derepressed M. morganii are typically susceptible to piperacillin/tazobactam whereas AmpC-derepressed strains of other species are resistant (Table III) . Penem and carbapenem inhibitors such as BRL 42715 69 and the olivanic acids 64 have wider spectra, inactivating Class A, C and D enzymes, but none has been developed commercially. Experimental monobactams such as Ro 48-1256 70 ( Figure 3 ) inhibit Class C -lactamases, but not other types. Class B enzymes are universally resistant to available inhibitors and to any experimental agent that has reached advanced development. Recent data, however, show that they are inhibited by mercaptoacetic acid thiol esters. 71 
-Lactamase quantity
It is harder to potentiate -lactams against isolates with high levels of -lactamase than against those with low levels. Amounts of TEM enzymes vary 150-fold among isolates and this variation is reflected in the concentrations of inhibitors required to potentiate penicillins. 72, 73 The effect of enzyme quantity is more complicated where a -lactamase is inducible, since the power of the inhibitor as an inducer and the activity of its partner -lactam affect susceptibility. Sulphones and clavams inhibit staphylococcal penicillinase, but also induce its production, so potentiation of partner penicillins is incomplete; 74 more specifically clavulanate induces AmpC -lactamases, which it cannot inhibit, and so tends to antagonize ticarcillin, itself a labile weak inducer, against some E. cloacae and M. morganii strains (Table III) . 
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Partner -lactam
It is easier for an inhibitor to protect a compound against which a -lactamase has little activity than one which is easily hydrolysed. In particular, it is easiest to protect a compound for which the -lactamase has low affinity, since the enzyme is then more likely to bind the inhibitor than the substrate. These points are highly relevant when comparing tazobactam and clavulanate combinations. Both inhibitors are similarly active against TEM-1 enzyme, but clavulanate is combined with amoxycillin and ticarcillin, to which the enzyme producers are highly resistant (MIC = 512-4096 mg/L), whereas tazobactam is combined with piperacillin, to which resistance is more modest (MIC = 32-512 mg/L). Thus, Enterobacteriaceae with TEM enzymes more often remain susceptible to piperacillin/ tazobactam than to amoxycillin/clavulanate or ticarcillin/ clavulanate. 72 
Organism effects
It is easier for an inhibitor to potentiate -lactams against highly permeable organisms. Thus, Neisseria gonorrhoeae and H. influenzae isolates with TEM-1 -lactamase are almost all susceptible to amoxycillin/clavulanate, but up to 25% of E. coli isolates with this enzyme are resistant. At the other extreme, it is difficult to potentiate -lactams against P. aeruginosa isolates with inhibitor-sensitive -lactamases, 66 because the organism is impermeable, or can pump out -lactams. A few species, notably Acinetobacter, but also some Bacteroides spp. and Burkholderia cepacia, are susceptible to inhibitors themselves: in the extreme case some Acinetobacter isolates are susceptible to sulbactam but to no other -lactam. 75 
pH
Many class A enzymes, including TEM-1, SHV-1 and staphylococcal penicillinase, are more susceptible to inhibition by penicillanic acid sulphones at mildly alkaline pH (7.5-8.0) than under neutral to mildly acidic conditions (pH 6.5-7.0), 15, 76 whereas the inhibitory power of clavulanate is independent of pH. This behaviour of the sulphones probably reflects tautomerization of the enzyme-inhibitor complex to a more stable form under the alkaline conditions. 77 Its clinical significance is unknown.
Piperacillin/tazobactam
Tazobactam is a good inhibitor of most Class A -lactamases 66, 78 (Table V) and piperacillin is a broadspectrum penicillin, to which many -lactamases give a moderate to high level of resistance (Table III) . These factors define the spectrum of the combination, although activity against individual strains is modulated by -lactamase quantity, bacterial permeability and, possibly, efflux mechanisms. Tazobactam extends the activity of piperacillin to include those genera-notably Bacteroides and Klebsiella-that have significant levels of chromosomal Class A -lactamases (Table III) . 79, 80 Although many isolates of these genera have been reported to be susceptible to piperacillin, it has long been apparent that piperacillin-hydrolysing activity is typically present. 10, 12 More importantly, tazobactam restores the activity of piperacillin against most organisms that have acquired plasmid-mediated Class A -lactamases, including staphylococci with penicillinases and Enterobacteriaceae with TEM or SHV enzymes (Table III) . 78 Reversal of piperacillin resistance caused by staphylococcal penicillinase is incomplete in vitro, 74 ,76 but appears adequate in vivo. In the case of E. coli and other Enterobacteriaceae with TEM-1, -2 and SHV-1 enzymes, MICs of piperacillin are reduced to 16 mg/L in >95% of cases. 72 Likewise, susceptibility to piperacillin is restored in 70% of klebsiellae with ESBLs, and in a greater proportion of those from many West European centres.
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Resistance to piperacillin/tazobactam in a minority of ESBL producers may reflect either the type or amounts of -lactamase; in particular, it has been suggested that many of the SHV-derived ESBLs are less sensitive to tazobactam than the TEM derivatives. 81, 82 Piperacillin itself retains good activity against most P. aeruginosa, pneumococci, streptococci and Enterococcus faecalis, where -lactamase-mediated resistance is rare or unknown. Adding these factors together, piperacillin/tazobactam has broad activity against common hospital pathogens, exceeded among -lactams only by that of the carbapenems. Substantial resistance to piperacillin/ tazobactam is largely confined to mutants of Enterobacter spp., C. freundii and Serratia spp. that hyperproduce AmpC enzymes (Table III) , to the few strains with Class B -lactamases and to bacteria with -lactamaseindependent piperacillin resistance, notably Enterococcus faecium and methicillin-resistant staphylococci. 80 How long will piperacillin/tazobactam maintain this spectrum? As with earlier -lactams, use will select resistance. Apart from the increasing numbers of isolates with AmpC or Class B enzymes, it is disturbing to note the emergence of inhibitor-resistant TEM mutants. Thirteen such variants have been described from clinical isolates, each with one or two amino acid substitutions. 83 
Prospects for new -lactams
Until now, it has been possible to 'redesign' -lactams to overcome resistance. This was relatively easy when only a few -lactamase types were important. Compounds were sought for stability to whatever enzyme-staphylococcal penicillinase, TEM-1 or AmpC-was perceived as the 'single great problem'. The increasing diversity of important -lactamases now undermines this approach. Cefepime and cefpirome provide examples of compounds overtaken by events. They were developed for their stability to AmpC enzymes, but now enter a microbial arena where ESBLs, to which they are labile, are increasingly prevalent. Over the past decade, it has been an obvious strategy to favour penems and carbapenems for development, to overcome both AmpC enzymes and ESBLs. However, the emergence of IMP-1, the plasmidencoded Class B enzyme, calls this approach into question, for it seems likely that this will spread in the 7-8 years it takes to develop a new compound. In the medium term, it may prove possible to modify penems or carbapenems to achieve stability to Class B enzymes, but no such derivative has yet been reported in the literature. Greater -lactamase diversity also complicates the design of inhibitors. It no longer appears adequate to seek compounds, such as the present clavams and penicillanic acid sulphones, active only against Class A and some Class D enzymes. Potent activity against AmpC enzymes is a sine qua non. Activity against Class B enzymes may also become desirable, but it appears unlikely that activity against both serine and zinc enzymes could be combined in a single molecule. In the future, because of the increasing diversity of important -lactamases and the increasing number of isolates with multiple enzymes, it may become necessary to protect antibacterial -lactams with more than one inhibitor for empirical therapy. In addition to the -lactamases reviewed here, it should be emphasized that target-mediated resistance is increasing. Particular concerns include PBP by-pass mechanisms in methicillinresistant staphylococci and E. faecium, and modification of the normal PBPs, via mutation and mosaic gene formation, in pneumococci, haemophili and Neisseria spp. 84 These mechanisms compromise all -lactams, although some agents retain clinically acceptable activity (e.g. cefotaxime, ceftriaxone and meropenem against many penicillin-resistant pneumococci). It is inherently harder to find -lactams that bind to altered PBPs than those stable to -lactamases and, in cases where resistance is contingent on the evolution of multiple mosaic PBPs, it is uncertain whether single -lactam nuclei could be designed to bind all the variants. Carbapenems and cephalosporins that can bind to PBP2 of methicillinresistant staphylococci have been described and may become available in the future, but they may not be broadspectrum compounds. Indeed, unless novel -lactams can be found, it is hard to escape the conclusion that we have seen the best of the broad-spectrum -lactams. Thus, more than anything, the opportunities for control of resistance lie in the careful and prudent use of the powerful compounds that are available-including piperacillin/ tazobactam and the carbapenems-rather than in undue optimism about any 'next generation' of -lactams. 
